3 Penny Stocks To Watch To Start The Week
Penny stocks are once again at the center of attention on Monday. These low priced shares are some of the most aggressive, high-risk investments anyone can make. But with the right strategy and risk tolerance, you can consistently make money with penny stocks.
There are a few big things going on this week to be aware of. First, it’s the last week of the month it’s also the final week before the U.S. Presidential election. During election years, volatility can play a huge role in market trends. Furthermore, we’re still going to see another round of economic data to digest.
Read More
- Making A List Of Penny Stocks To Buy Right Now? 3 To Watch This Week
- 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
“Historically, the stock market has performed far better the year after elections when the incumbent party candidate wins but also when the winner is a Democrat, a combination that clearly cannot happen in 2021,” Citi Private Bank’s Steven Wieting observed.
Penny Stocks To Watch:
- GT Biopharma (GTBP Stock Report)
- Advaxis (ADXS Stock Report)
- Geovax Labs (GOVX Stock Report)
In a week that is sure to see volatility, there are a plethora of earnings as well. Everything from tech to healthcare will report this week. What’s more, is that some of the biggest names will reveal their 3rd quarter results. Amazon.com, Apple, Facebook, Google’s parent company Alphabet, and Microsoft all report this week. Will that impact penny stocks today? We’ll have to see. However, in light of the recent market momentum, here are some top penny stocks to watch right now.
Penny Stocks To Watch: GT Biopharma Inc.
GT Biopharma (OTC:GTBP) is one of the more active, small-cap biotech penny stocks to watch recently. The company has been delivering consistent news over the last month or so. When it comes to biotech stocks, phase trial data is a key indicator of progress. In light of this, we’ve seen a few things come about that have brought attention to the company. In late-September, GT Biopharma announced data from the Dose Level 3 portion of its Phase I/II trials for GTB-3550 for treating acute myeloid leukemia. GTB-3550 at a 25mcg/kg/day dose showed a decrease in AML blast levels from 18% to 12% in the bone marrow. All of these findings support the clear potential that GTB-3550 could hold and that’s just for one indication right now.
Fast-forward to the end of October and there are several things that have happened and are coming up to note. GTB-3550 were selected for presentation at the 62nd (ASH) American Society of Hematology Annual Meeting. While the meeting is set for December, the company pointed out that in addition to the presentation, “your abstract will also be published online in November supplemental issue of the journal Blood”.
What To Watch With GT Biopharma
The first publication will be in the online ASH meeting program on November 5, 2020. In addition, the platform that GTB-3550 is built on, which is the company’s TriKE™ technology, has gotten a lot more attention recently.
Last week the company announced a publication in the journal Cancers, which demonstrated TriKE™ had the potential to enhance natural killer cell immunotherapy in solid tumor settings and supported its further clinical development. TriKE™ has been evaluated in ovarian, breast, prostate, pancreatic ductal adenocarcinoma, and lung cancer models. With growing interest in immunotherapy stocks, GTBP has gained the interest of traders this quarter. Will that continue as the case heading into the end of October?
Penny Stocks To Watch: Advaxis Inc.
Another one of biotech penny stocks to watch right now is Advaxis Inc. (NASDAQ:ADXS). The company announced key developments with is ADXS-503 treatment this week. On Monday, the company reported updated clinical results from the combination arm of its ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®. ADXS-503 is built on the company’s ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program. Also, if you weren’t aware, KEYTRUDA® is Merck’s anti-PD-1 therapy in non-small cell lung cancer (NSCLC).
What To Watch With Advaxis
Results included disease control rate of 67% (4/6 patients) and overall response rate of 17% (1/6 patients). This was achieved after immediate prior progression on KEYTRUDA® with previous best responses of stable disease.
“This improvement in the setting of uninterrupted treatment on KEYTRUDA® is promising and suggests that ADXS-503 may be capable of re-stimulating the immune system to drive clinically meaningful benefit. The sustained durability of responses is also noteworthy, and I look forward to the continued evaluation of ADXS-503 in additional patients as we advance through the efficacy expansion phase of the study.”
Ken Berlin, Chief Executive Officer of Advaxis.
Shares jumped premarket on Monday to highs of $0.6298. As the market opened, the penny stock slid back to around $0.45. The biggest question is will these data support a more upbeat sentiment in the market for ADXS stock right now or is this set to continue its slide from the end of last week?
Penny Stocks To Watch: GeoVax Labs, Inc.
GeoVax Labs (NASDAQ:GOVX) made headlines as well on Monday. The company focuses on immunotherapies, similar to the other names on this list. However, in this case, GeoVax announced some coronavirus-related news today. Over the weekend, new records were reached in new cases, which has definitely brought more focus or more of a re-focus on coronavirus stocks to begin the week.
[Read More]What Are The Best Penny Stocks To Buy Right Now? 3 Names To Know
GeoVax announced a a Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases. This is part of the National Institutes of Health, and will support GeoVax’s development of a vaccine against SARS-CoV-2. According to the company, the aggrement includes access to NIAID’s patent rights in the stabilized SPIKE protein. This SPIKE protein is the one that SARS-CoV-2 uses to gain entry into human tissue.
What To Watch With GeoVax
This adds to the growing list of vaccine candidates that GeoVax has designed. Currently that figure sits at 4 and the company has set a goal of providing a single-dose vaccine against multiple types of coronavirus.
“We anticipate that multiple COVID-19 vaccines will be necessary for the goal of broad public health protection, especially in addressing the preventive needs among populations with compromised immune systems, including people with co-morbidities and older adults.
David Dodd, GeoVax President and CEO
With both price and volume surging on Monday, will GOVX stock be one to watch throughout the last week of October?
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
